These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 11059635

  • 1. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F.
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [Abstract] [Full Text] [Related]

  • 2. Preserving Target-organ Function with Candesartan Cilexetil in Patients with Hypertension.
    Zannad F.
    Blood Press; 2000; 9(sup1):36-39. PubMed ID: 28425806
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P.
    Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
    [Abstract] [Full Text] [Related]

  • 4. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

  • 5. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P.
    Blood Press Suppl; 2000; 1():23-6. PubMed ID: 11059632
    [Abstract] [Full Text] [Related]

  • 6. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 7. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
    Ruilope L.
    Blood Press Suppl; 2000 Sep; 1():31-5. PubMed ID: 11059634
    [Abstract] [Full Text] [Related]

  • 8. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT, O'Kane KP, Jonker J, Roth J.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [Abstract] [Full Text] [Related]

  • 10. Reducing cardiovascular morbidity and mortality in the elderly.
    Trenkwalder P.
    Blood Press Suppl; 2000 Sep; 1():40-3. PubMed ID: 11059636
    [Abstract] [Full Text] [Related]

  • 11. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
    Omoto K, Tanabe K, Tokumoto T, Shimmura H, Ishida H, Toma H.
    Transplantation; 2003 Oct 27; 76(8):1170-4. PubMed ID: 14578748
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K, Kahan T, Dahl M.
    Am J Hypertens; 2000 May 27; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [Abstract] [Full Text] [Related]

  • 13. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T, Arakawa K.
    J Hum Hypertens; 1999 Jan 11; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [Abstract] [Full Text] [Related]

  • 15. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep 11; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

  • 16. Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design.
    Andersen NH, Knudsen ST, Poulsen PL, Poulsen SH, Helleberg K, Eiskjaer H, Hansen KW, Bek T, Mogensen CE.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun 11; 4(2):96-9. PubMed ID: 12806591
    [Abstract] [Full Text] [Related]

  • 17. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K, Naka T, Chatani F, Yoshimura Y.
    J Hum Hypertens; 1997 Sep 11; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [Abstract] [Full Text] [Related]

  • 18. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G, Fuchs W.
    Curr Med Res Opin; 2005 Jun 11; 21(6):935-40. PubMed ID: 15969893
    [Abstract] [Full Text] [Related]

  • 19. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
    Asmar R, Porcellati C, Dusing R.
    Drugs Exp Clin Res; 2004 Jun 11; 30(4):153-61. PubMed ID: 15553661
    [Abstract] [Full Text] [Related]

  • 20. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS.
    J Hypertens Suppl; 1997 Dec 11; 15(6):S9-12. PubMed ID: 9493121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.